12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-26), Myriad Genetics's 12-1 Month Momentum % is 2.43%.
The industry rank for Myriad Genetics's 12-1 Month Momentum % or its related term are showing as below:
MYGN's 12-1 Month Momentum % is ranked better than 68.35% of 237
companies
in the Medical Diagnostics & Research industry
Industry Median: -17.44
vs MYGN: 2.43
Competitive Comparison of Myriad Genetics's 12-1 Month Momentum %
For the Diagnostics & Research subindustry, Myriad Genetics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics's 12-1 Month Momentum % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Myriad Genetics 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Myriad Genetics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Myriad Genetics (Myriad Genetics) Business Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYGN has been successfully added to your